Article Text

PDF
Heart failure
Cells as biologics for cardiac repair in ischaemic heart failure
  1. Jozef Bartunek1,2,
  2. Marc Vanderheyden1,
  3. Jonathan Hill3,
  4. Andre Terzic4
  1. 1Cardiovascular Center, OLV Ziekenhuis Aalst, Belgium
  2. 2Department of Soft Tissue Engineering, University of Technology, Eindhoven, The Netherlands
  3. 3Division of Cardiology, King's College, London, UK
  4. 4Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Jozef Bartunek, Cardiovascular Center, OLV Ziekenhuis, Moorselbaan 164, 9 300 Aalst, Belgium; jozef.bartunek{at}olvz-aalst.be

Statistics from Altmetric.com

The epidemic of heart failure due to coronary artery disease is a leading cause of morbidity and mortality worldwide. The hallmark of this pathology is maladaptive ventricular remodelling that precipitates contractile dysfunction, and ultimately leads to the overt syndrome of congestive heart failure. The central feature in this malignant cascade is the massive loss of cardiomyocytes, followed by replacement with fibrotic scar; this ultimately leads to organ failure which is further accelerated by haemodynamic overload, inflammatory–oxidative stress, and/or impaired vascularisation. Despite continuous advances in disease management, the available medical, interventional or surgical treatments fall short of addressing the root cause of disease and are typically limited to palliative strategies mitigating disease symptomatology.

The rationale for stem cell based regenerative medicine applied to the treatment of heart diseases is based on the realisation that natural self renewing processes innate to the myocardium, while sufficient to sustain normal homeostasis, fall short of salvaging heart muscle following massive injury—as in the setting of myocardial infarction.1 Accordingly, boosting the cardiac reparative capacity through supplementation of stem cell pools has been increasingly considered as a novel therapeutic approach. Indeed, it is now recognised that extracardiac (eg, bone marrow) in addition to intracardiac progenitor cells are mobilised and home to the site of the myocardial injury to participate in the compensatory healing response.1 w1 Furthermore, there is growing evidence that such cells participate in the maturation and induction of collateral vascular growth and neovasculogenesis, and may acquire phenotypic properties of neighbouring cardiac myocytes.1 These findings, propelled by recent progress in developmental biology, offer an unprecedented opportunity to achieve repair of damaged myocardium using stem cells as new therapeutic tools. Here, we focus on the current clinical experience as well needs for successful translation of the emergent field of cell based therapy from proof-of-concept …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.